Table 3.
Seroresponse Rates and Geometric Mean Concentrations/Titers (GMC/Ts) for Antibodies to Measles, Mumps, and Rubella Viruses at Day 42 in Initially Seronegative Subjects (According-to-Protocol Cohort for Immunogenicity)
| Measles (≥200 mIU/mL) |
Mumps (≥51 ED50) |
Rubella (≥10 IU/mL) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Seroresponse |
GMC (95% CI) | N | Seroresponse |
GMC (95% CI) | N | Seroresponse |
GMC (95% CI) | |||
| n (%) (95% CI) | % Diff. vs. MMRII (95% CI) | n (%) (95% CI) | % Diff. vs. MMRII (95% CI) | n (%) (95% CI) | % Diff. vs. MMRII (95% CI) | ||||||
| MMR-RIT-1 | |||||||||||
| 247 | 245 (99.2) (97.1; 99.9) | −0.41 (−2.55; 1.50) | 2799 (2545; 3078) | 193 | 175 (90.7) (85.7; 94.4) | −0.47 (−6.42; 5.46) | 242 (205; 287) | 247 | 244 (98.8) (96.5; 99.7) | −1.21 (−3.51; 0.32) | 72.2 (65.6; 79.6) |
| MMR-RIT-2 | |||||||||||
| 240 | 236 (98.3) (95.8; 99.5) | −1.27 (−3.85; 0.74) | 2878 (2607; 3178) | 202 | 183 (90.6) (85.7; 94.2) | −0.55 (−6.41; 5.35) | 265 (222; 317) | 238 | 235 (98.7) (96.4; 99.7) | −1.26 (−3.64; 0.27) | 77.7 (70.4; 85.7) |
| MMR-RIT-3 | |||||||||||
| 240 | 236 (98.3) (95.8; 99.5) | −1.27 (−3.85; 0.74) | 2593 (2350; 2861) | 195 | 175 (89.7) (84.6; 93.6) | −1.40 (−7.47; 4.62) | 253 (213; 301) | 239 | 233 (97.5) (94.6; 99.1) | −2.51 (−5.37; −0.97) | 68.2 (61.8; 75.3) |
| MMRII | |||||||||||
| 249 | 248 (99.6) (97.8; 100) | Reference | 2950 (2698; 3224) | 192 | 175 (91.1) (86.2; 94.8) | Reference | 268 (224; 320) | 249 | 249 (100) (98.5; 100) | Reference | 89.4 (81.4; 98.2) |
Abbreviations: MMR, measles-mumps-rubella; N, number of subjects with available results; n (%), number/percentage of subjects who seroconverted; 95% CI, 95% confidence interval; GMC/T, geometric mean concentrations/titers for measles, mumps, and rubella virus antibodies.